Hormonal
Tirzepatide and Mazdutide, as dual-receptor agonists, offer superior glucose-lowering and weight loss efficacy compared to conventional GLP-1RAs, but their high cost and lack of reimbursement limit their overall recommendation status.
Tirzepatide and Mazdutide are powerful dual-receptor agonists that offer superior glucose and weight loss benefits compared to conventional GLP-1RAs. However, their high cost and lack of insurance coverage in China make them less accessible. Patients should discuss these options with their doctors, considering both efficacy and affordability. If cost is a barrier, Semaglutide and Dulaglutide are strong alternatives with established cardiovascular benefits.
Tirzepatide reveals superior glucose-lowering compared to dulaglutide in the SURPASS-CVOT study... Tirzepatide leads the field with substantial reductions of 11–13% in the SURPASS and SURMOUNT trials... Mazdutide is Not Recommended currently due to insufficient evidence, absence from the national reimbursement drug list, and high cost.
Why this rating
Based on systematic literature review, clinical trials (SURPASS, SURMOUNT, DREAMS-3), and real-world data.
Source
A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management
Qiying Chen et al. · Diabetes Metabolic Syndrome and Obesity · 2026
DOI 10.2147/dmso.s585436
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →